Detection of the Leprosy Agent Mycobacterium lepromatosis in South America and Europe

Han, Xiang Y.

doi:10.4269/ajtmh.16-0713

Cited by 17 publications

(20 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…According to our findings, M. lepromatosis may cause the NLL and BL ( Table 1). Given that M. lepromatosis is not geographically restricted to Mexico as it has been identified in America and Asia; Brazil, Myanmar, Canada, and Singapore 12,[15][16][17][18][19] , and that it can participates in dual infections in Leprosy endemic areas, M. lepromatosis should be taken on account for diagnosis worldwide. However as it has been observed in another papers DLL is related only with M. lepromtosis alone or with dual infection, but not only with M. leprae, it could explain the severity of these cases 13 .…”

Section: Dna Extraction and Polimerase Chain Reaction (Pcr)mentioning

confidence: 99%

Identification ofMycobacterium lepraeandMycobacterium lepromatosisin Formalin-Fixed and Paraffin-Embedded Skin Samples from Mexico

et al. 2018

View full text Add to dashboard Cite

Background: The causative agents of leprosy are the well-known Mycobacterium leprae and the newly discovered Mycobacterium lepromatosis. This agent was found in 2008, and it was found to be the cause of diffuse lepromatous leprosy in two Mexican patients. Objective: The objective of this work was to determine if M. leprae and M. lepromatosis were present in formalin-fixed and paraffin-embedded skin samples from cases from different regions in Mexico. Methods: A total of 41 skin samples were obtained from 11 states of Mexico. All patients' samples were diagnosed by clinical and histopathological analyses. Total DNA was isolated using a Qiagen-DNeasy blood and tissue kit and molecular identification was achieved by two semi-nested polymerase chain reactions. Results: The 41 patient included 33 samples from men and 8 samples from women; 29 samples were polymerase chain reaction (PCR)-positive to Mycobacterium and 12 samples were PCR-negative. From those 29 samples, 13 were PCR-positive to M. leprae, 8 to M. lepromatosis and 8 were positive to both species. The histopathological diagnosis included; Nodular lepromatous leprosy (NLL); Diffuse lepromatous leprosy (DLL); and Borderline leprosy (BL). The 29 PCR-positive samples were classified as follow: 14 NLL, 4 DLL, and 11 BL. In the 12 samples negative to Mycobacterium, 7 showed the NLL, 2 DLL and 3 BL. Conclusion: These findings add evidence to the M. leprae and M. lepromatous distribution, clinical forms and participation of dual infections in Mexico.

show abstract

Section: Dna Extraction and Polimerase Chain Reaction (Pcr)mentioning

confidence: 99%

Identification ofMycobacterium lepraeandMycobacterium lepromatosisin Formalin-Fixed and Paraffin-Embedded Skin Samples from Mexico

et al. 2018

View full text Add to dashboard Cite

show abstract

“…38 It has been reported in Mexico, Brazil, Singapore, Canada, Myanmar, and most recently in India. [39][40][41][42] Initially thought to have a worse prognosis, it has since been reported to have a similar clinical course and response to treatment as M. leprae. 38 Eleven cases have been described in the United States, most recently in 2017 at the Mayo Clinic.…”

Section: Variantmentioning

confidence: 99%

Neurological Complications of Leprosy

Lau

2019

Semin Neurol

View full text Add to dashboard Cite

Leprosy is a challenging international health concern. Despite tremendous efforts in reducing worldwide disease prevalence in the past decades, some countries remain endemic and are plagued by high levels of disability. The neurological complications of leprosy are varied and complex, with current research focused on evaluating tools for earlier diagnosis of neuropathy, especially in resource-limited countries. While treatment with multidrug therapy is highly effective, active research aims to simplify regimens to improve adherence, minimize adverse effects, and prevent antimicrobial resistance. Although promising progress has been made in the past decades, further efforts are needed to push the international community toward achieving worldwide elimination.

show abstract

“…Several studies have shown that M. lepromatosis is the long-elusive second agent of leprosy ( 8 – 14 ). The organism has been identified so far in leprosy patients from Mexico ( 8 – 10 ), Canada ( 11 ), Brazil ( 12 ), Burma ( 12 ), and Singapore ( 13 ). It is likely the dominant cause of leprosy in Mexico ( 9 ).…”

Section: Genome Announcementmentioning

confidence: 99%

“…It is likely the dominant cause of leprosy in Mexico ( 9 ). Dual infections with both M. lepromatosis and M. leprae have been described ( 8 , 12 , 13 ). Like M. leprae , M. lepromatosis has not been cultivated in medium so far.…”

Section: Genome Announcementmentioning

confidence: 99%